Madison-based Cellectar Biosciences (fka Novelos Therapeutics, Inc.) has reported a net loss in 2013 of $10.8 million (19 cents/share), compared to its $9.3 million loss (23 cents/share) in 2013. The company reported higher research and development expenses related to preparations for clinical trials: one for a product to image brain cancer, another designed to correctly dose a compound used to treat cancerous tumors. The company is hoping to begin a third study by the end of the year related to imaging the borders of breast cancer tumors.
Get Our Email Newsletter
The companies, people and issues shaping business in Madison and the Capital Region.
